Anti-drug Antibodies

Benefits of characterizing the anti-drug response

Peptide-based epitope mapping is a powerful tool for the identification of immunogenic sites within the drug molecule. In general protein-based therapeutics are highly selective and biocompatible. Consequently, they enjoy relatively low failure rates in development: about a quarter of biopharmaceuticals successfully pass clinical trials (Ecker et al., 2015, mAbs). Despite their undisputable advantages, in clinical trials biopharmaceuticals occasionally induce unwanted immune responses – production of anti-drug antibodies (ADAs). Immunogenicity thus decreases or eliminates the drug’s efficiency and efficacy and can even prohibit its approval for use in humans, as ADAs can cause allergic reactions and severe adverse effects. Given the importance of assessing drug immunogenicity sets of methods that identify and characterize ADAs need to be developed. Several techniques mainly targeted at charting the response at large are available, yet lack the resolution to allow differentiation between different types of ADAs, e.g. those that affect drug effects or those that may be asymptomatic.
Here Pepscan peptide mini-arrays have numerous advantages making their application for the ADA identification superior to other methods:

  • high peptide density allows identification of ADAs in low concentrations and even at low affinities
  • re-usability of the arrays allows testing tens of clinical samples (sera, ascites, plasma) with one peptide set
  • single residue precision by libraries of all overlapping peptides
  • broad applicability to all kind of protein-based molecules with no limitation to size/PTMs

CLIPS Precision Epitope Mapping also enables identification of structure-specific ADAs, a key advantage over simple linear mapping techniques. Pepscan peptide arrays allow performing full substitution analysis on identified ADAs epitope sequences. This easily identifies single residue substitutions, which allow grasping the breadth of ADA binding to the sequence of the biotherapeutic. Results of epitope mapping studies allow detailed assessment and tight control of the ADA populations in patient samples during all stages of drug development. In certain cases epitope mapping results may inspire elimination strategies, alterations to the therapeutic, or allow finding those subgroups of patients who do not possess neutralizing antibodies.

Case example

To demonstrate how epitope mapping can help to analyze ADAs in a set of clinical samples we mapped peptide binding intensities obtained for 23 patient samples on a library of 400 peptides designed from a protein drug sequence. Intensity profiles for each sample were averaged, scaled and then clustered. The resulting heatmap is shown below.

Heatmap ADA

Heatmap analysis showing the polyclonal response from patient sera. Each column corresponds to the response for a certain sample on all peptides and each row corresponds to the response obtained for all samples with one peptide. Data were scaled and clustered. Red arrows indicate regions that are commonly recognized by antibodies in all samples and green arrow indicates a region which is uniquely recognized only by certain patients (possibly, neutralizing antibodies).

The heatmap shows that antibody binding profiles may point to the presence of four immunogenic regions within the drug molecule – three dominant regions (red arrowheads) and one specific region (green arrowhead) present only in certain samples. The latter potentially represents a population of ADAs which may neutralize the drug’s action.

FDA and EMA guidelines stress the importance of characterizing ADAs in full detail during all stages of drug development:

“An understanding of the increased immunogenicity (…) will require more complete characterization of the ADA response, such as identification of the target epitope(s).”

In: FDA Guidance for Industry. Immunogenicity Assessment for Therapeutic Protein Products (August 2014)

The only technology for all types of epitopes:
Linear, conformational and discontinuous

Re-usable arrays for multiple screenings:
Comparative mapping and epitope fingerprinting of up to 100’s of samples

Highest sensitivity through high peptide density:
Also effective for weakly binding antibodies

Structurally & functionally customized peptide arrays:
Include post-translational modifications, cyclizations, helices, β-sheets

Applicable to all kinds of samples:
Mabs, antibody-like scaffolds and polyclonal sera

Applicable to all kinds of target proteins:
Soluble as well as membrane integrated proteins, viral capsids

Unrivalled single residue resolution:
Solid support for patent claims and Freedom to Operate assessments

Reliable, fast and cost-effective:
No-crystallization required, multiple screenings on one array

Full service with minimal material consumption:
20 μg antibody or 20 μl of serum + target protein sequence (Uniprot/FASTA)

Epitope fine mapping: revealing fine details of anti-HIV-1 F425-B4e8

Having a detailed understanding of the binding specificity of an antibody surely is appealing from the perspective of basic science, but also to secure IP or ensure freedom to operate.  Epitope fine mapping defined the fine features of an anti-HIV-1 antibody and provided a unique insight into the breadth of HIV strains that can be recognized by this antibody.

Download this Case Report

FDA breakthrough therapy designation for two Pepscan-mapped antibodies

Two antibodies for which Pepscan was asked to perform the epitope mapping, recently received breakthrough therapy designation by the FDA. It concerns Roche/Genentech’s anti-CD20 mAb obinutuzumab and Genmab/Johnson & Johnson’s anti-CD38 mAb daratumumab. We are proud to have contributed to these projects and congratulate our clients with their success.

Download this Case Report

Revealing the discontinuous epitope of human anti-SIRPα in full detail

The epitope of an anti-SIRPα antibody, which cannot be mapped either with linear peptides or with structural mimics, was successfully elucidated via CLIPS Precision Epitope Mapping using a comprehensive library of combinatorial CLIPS peptides based on the sequence of SIRPα.

Download this Case Report

Determining the discontinuous epitope of the anti-CD38 antibody daratumumab

CD38 is a 46kDa trans-membrane glycoprotein highly expressed in hematological malignancies. A two-stage CLIPS Precision Epitope Mapping strategy precisely determined the discontinuous epitope for daratumumab on the membrane-bound CD38.

Download this Case Report

Conformational Epitope Mapping of a Flu Virus Antibody

FI6 is a monoclonal antibody that potentially neutralizes all influenza viruses. To reveal the molecular basis of this pan-influenza cross-reactivite antibody, we fine-mapped the conformational epitope recognized by FI6. (Corti et al, Science 2011).

Download this Case Report

The molecular basis for distinction between GA-101 and Rituximab

Rituximab, a monoclonal antibody targeting CD20, has improved the treatment of malignant lymphomas. Therapeutic CD20 antibodies are classified as either type I or II based on different mechanisms of killing malignant B cells. To reveal the molecular basis of this distinction, we fine-mapped the epitopes recognized by Rituximab (Type I) and novel GA101 (Type II).

Download this Case Report

Conformational Protein-Protein Interaction Mapping of etanercept (Enbrel®)

The CLIPS Epitope Mapping technology has been shown an effective tool for mapping of conformational and discontinuous epitopes of therapeutic antibodies. This case study demonstrates that the technology can also be used to identify the interaction site between hormones and cell-bound receptors. Etanercept (Enbrel®) is a chimeric TNFa receptor that is used to treat autoimmune disease by interfering with TNFa (tumor necrosis factor). The interaction between Etanercept and the TNFa trimer was studied in full detail through the CLIPS Mapping technology.

Download this Case Report

Epitope Fingerprinting of large sets of disease-related polyclonal sera

Pepscan’s CLIPS Epitope Mapping not only suitable for precision mapping of one single antibody , but also for detailed epitope fingerprinting analysis of large sets of antibodies or polyclonal sera. This case report demonstrates the application in profiling the epitope landscapes of large numbers of sera from diseased and healthy origin to identify epitopes linked to protection.

Download this Case Report

Precision Epitope Mapping: how does it work?

Using its extensive expertise in peptide synthesis and vaccine development Pepscan has developed the Precision Epitope Mapping platform to profile all types of epitopes for big panels of biological samples (antibodies and antibody fragments, purified proteins and sera). Applying its thorough expertise in structured peptides, Pepscan generated various strategies in addressing linear, conformational and discontinuous epitopes via fully customized library designs and bio-informatical data analysis tools.

The concept of mapping linear epitopes using libraries of overlapping synthetic peptides was for pioneered by Pepscan founders Geysen and Meloen. Since then this technology was widely applied by many companies and research groups for various projects. As the inventor of the technology Pepscan has long standing expertise in addressing linear epitopes by directly synthesizing libraries of linear peptides on a solid support covered with a proprietary hydrogel formulation, which allows working with biomolecules and can be easily regenerated for profiling big sample sets. To generate a library of linear mimics, the correct amino acid sequence of the immunogen (or target protein) is split in overlapping fragments in silico, which are then synthesized on a solid support. Once the linear array is synthesized, binding of a test antibody to such library is quantified and compared via an ELISA. When the epitope sequence is present in linear peptides, the antibody avidly binds this set of peptides (as schematically shown below).

Linear concept

The target linear sequence is converted into a library of all overlapping linear peptides directly synthesized on a proprietary solid support called “mini-card”. Binding of antibodies is quantified using an automated ELISA-type read-out. Constructs containing right amino acid sequence in the correct conformation best bind the antibody.

However, the majority of biomolecules of therapeutic interest recognize conformational or discontinuous epitopes, which cannot be reliably (if at all) addressed by means of linear epitope mapping. For many antibodies the primary sequence of amino acids is not sufficient for binding and additional 3D structure features are needed. This is why Pepscan perfected its platform to enable systematic mapping of conformational and discontinuous epitopes.

One example is creating simple secondary structure mimics by applying different CLIPS scaffolds allowing to thermodynamically favour a limited series of peptide conformations. In such a manner CLIPS peptide libraries can mimic secondary structure elements, such as loops, α-helixes and β-strands. A schematic representation of this approach is drawn in the figure below, where all three secondary structure elements present in the target’s 3D structure are mimicked using various CLIPS chemistry strategies.

Conformational concept

The target protein contains α-helixes, β-sheets separated by loops is converted into different conformational libraries using a CLIPS scaffold. Peptides are synthesized on a proprietary minicard and chemically converted into spatially defined CLIPS constructs (right). Binding of antibodies is quantified using an automated ELISA-type read-out. Constructs containing the right amino acid sequence in the correct conformation best bind the antibody.

It is also possible to create a large combinatorial library of CLIPS based tertiary structure mimics. Using a combinatorial matrix design and different CLIPS scaffolds, the target protein is converted into an extensive library of conformationally constrained mimics that has sequences which are not adjacent in the primary sequence brought together on a CLIPS scaffold. This library of CLIPS-based tertiary structure mimics is then synthesized on a solid support, using high-throughput microarray synthesis technology.
Subsequently the binding of the antibody to each construct of the entire library is determined, using an automated ELISA-type read-out. This identifies those CLIPS-constructs that best mimic the interaction site of interest. A schematic representation of the approach is presented in the figure below. Designed constructs containing both parts of the interaction site in the correct orientation are bound with the highest affinity by the test antibody, which is detected and quantified. Constructs representing theincomplete epitope bind the antibody with much lower affinity, whereas constructs not containing (parts of) the epitope are not bound by the antibody at all. Bioinformatic statistics-based analysis of the combined binding data is used to define the sequence and conformation of epitopes in detail. CLIPS Precision Epitope Mapping also allows detecting of conformational, discontinuous, and complex epitopes involving dimeric or multimeric protein complexes.

Discontinuous concept

The target protein containing a discontinuous conformational epitope (left cartoon) is converted into a library of linear peptides as well as CLIPS constructs via a combinatorial matrix design. Peptides are synthesized on a proprietary minicard and chemically converted into spatially defined CLIPS constructs (right). Binding of antibodies is quantified using an automated ELISA-type read-out. Constructs representing both parts of the discontinuous epitope in the correct orientation best binds the antibody.

Making surface-bound conformationally constrained peptide libraries

The Precision Epitope Mapping is based on Pepscan’s proprietary platform for making microarrays containing large libraries of surface-immobilized linear, secondary and tertiary structure CLIPS-based epitope mimics.
Using high-throughput parallel microarray synthesis technology, a full library of linear, conformational and discontinuous epitope mimics, is synthesized on a proprietary surface with a polymeric graft optimized for low non-specific binding and high peptide construct loading resulting in high sensitivity of the Precision Epitope Mapping technology. Via Pepscan’s patented CLIPS technology these peptides are structurally fixed into defined three-dimensional structures. This enables mimicking even the most complex binding sites.
The CLIPS technology is now routinely used to create peptide libraries of single- or double- looped structures, as well as sheet- and helix-like folds.

All mimics

Using the CLIPS technology, peptides derived from native proteins are transformed into CLIPS constructs with a range of structures. From left to right: linear, single mP2 loops, stabilized beta sheet, alpha helix, and T3 double loop.

Peptide synthesis FMOC chemistry. Maximum peptide length over 40 residues. All amino acids including D-amino acids and non-natural amino acids.
Capacity 50.000 peptides per run with custom high-througput parallel synthesis robots.
Peptide library format Proprietary ‘Minicard’ format with solid phase-bound peptide constructs in 455 microwells. Surface chemistry: proprietary polymeric graft optimized for low non-specific binding and high peptide construct loading.
Combinatorial library complexity Matrix analysis e.g. 50 x 50 = 2.500 double loop T3 CLIPS™. All matrix combinations within 40-mers possible. All overlapping single loops usually 15 – 20-mers. All overlapping peptides of a protein usually 15 – 20-mers. Full positional scan libraries of all epitopes.
Spatial construct complexity Single loops on T2 CLIPS.
Double loop combinations on T3 or 2 x T2 CLIPS
Sheet-like T2 CLIPS. Helix-like T2 CLIPS.
All loop structures with 2-6 cysteines and 1 or 2 CLIPS.
Peptide library reusability At least 20 times but up to 100 depending on the samples. Library storage and re-use up to years.
Binding detection Binding of the antibodies to the CLIPS peptides is determined in an ELISA. The resulting color in each well is quantified with a CDD camera.
Binding detection sensitivity Optimized for epitope mapping of even low affinity binding antibodies (down to Kd=10-3M)
Required material and information 20 μg antibody or 20 μl polyclonal serum. Sequence of target protein in FASTA format or UniProt ID.
Project run-through time Priority 1.5 months. Standard up to 3 months.
Reporting Binding values of all peptides are quantified and stored in the PepLab™ database. A full report is provided including details on binding and specificity for each residue optimized for registration regulatory and/or IP purposes. Full support is offered for IP generation and publishing.

Pepscan provides Precision Epitope Mapping as a complete end-to-end service. Supported by the expertise of our scientific team this allows each customer to fully benefit from all options the Precision Epitope Mapping technology offers.

A project usually starts with a discussion with the customer to define the project objectives. Before a project is discussed in detail, upon request, Pepscan is willing to sign a Confidentiality Disclosure Agreement (CDA) to assure absolute confidentiality.

Customer data input and sample requirements

  • Sequence of target protein in FASTA format or UniProt ID.
  • Minimal material consumption: 20 μg antibody or 20 μl polyclonal serum.

Tailor made project proposal

  • Full description of project study proposal
  • Timelines and budget

Design and synthesis of target-derived peptide arrays on re-usable "Minicards"

  • Design based on protein sequence (linear, single-loops, double loops)
  • Tailored additions to library based on 3D structure or customer input
  • Potential to address Post Translational Modifications

Screening of samples

  • On each re-usable Minicard up to 100 antibodies or sera can be screened
  • Data quantification
  • Storage in PepLab database

Extensive analysis of data

  • Matrix scan / Box plots / Heat maps
  • 3D imaging and modeling of protein
  • Mapping of epitopes on protein
  • Amino acid residue replacement analysis
  • Fine Mapping of epitopes on protein

Deliverable: a detailed report

  • Study design
  • Protocols
  • Experimental details
  • Results

Timelines

The timeline of a project starts with the design of the peptide arrays based on the sequence of target protein provided by the customer. Depending on the size of the target protein and the complexity of the project the synthesis of target-derived peptide arrays usually takes around 4 – 6 weeks. We usually ask to ship the sample(s) within this period. The duration of the screening depends on the number of samples to be tested, followed by 1-2 weeks for data analysis, evaluation and preparation of the report. In most cases a project is completed within 3 months, although more time may be needed for large series of samples.